| Literature DB >> 35816047 |
Hanhan Liu1, Katharina Bell2, Anja Herrmann3, Stefan Arnhold3, Karl Mercieca4, Fabian Anders5, Kerstin Nagel-Wolfrum6, Solon Thanos7, Verena Prokosch1.
Abstract
Purpose: The aim of this study was to explore the roles of crystallins in the context of aging in glaucoma and potential mechanisms of neuroprotection in an experimental animal model of glaucoma.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35816047 PMCID: PMC9284462 DOI: 10.1167/iovs.63.8.3
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.925
Antibodies Used in Microarray Analysis
| Antibody | Distributer/Manufacturer |
|---|---|
| Rabbit anti-human | Ab6201, Abcam, Cambridge, United Kingdom |
| Anti-ciliary neurotrophic factor ( | ABIN1585830, Antibodies Online GmbH, Aachen, Germany |
| Anti-interleukin 6 ( | GTX79381, Enzo Life Sciences, Israel |
| Anti-transforming growth factor-beta 1 ( | ABIN2998227, Antibodies Online GmbH, Aachen, Germany |
| Anti-transforming growth factor-beta 2 ( | ABIN2992615, Antibodies Online GmbH, Aachen, Germany |
| Anti-pigment epithelium-derived factor ( | ABIN4237861, Antibodies Online GmbH, Aachen, Germany |
| Anti-apolipoprotein E ( | ABIN258785, Antibodies Online GmbH, Aachen, Germany |
| Anti-nerve growth factor beta ( | ORB11126, Biorybt, Cambridge, United Kingdom |
| Anti-vascular endothelial growth factor A ( | Ab39250, Abcam, Cambridge, United Kingdom |
| Anti-clusterin ( | ABIN1077938, Antibodies Online GmbH, Aachen, Germany |
| Anti-complement factor H ( | PA5-24425, Thermo Fisher Scientific, Waltham, MA, United States |
| Anti-matrix metallopeptidase 9 ( | ABIN113587, Antibodies Online GmbH, Aachen, Germany |
Figure 1.Working hypothesis and workflow overview.
Figure 2.Abundance changes in alpha-crystallin B (, and gamma-crystallin B ( CRYAB, CRYBB2, and CRYGB show a clear increase in abundance within aging in response to chronically elevated IOP, the increase in the 10-day-old animals is particularly significant. The rate of the increase in all three crystallins decreases with ageing (10 days: n = 5, 12 weeks: n = 7, and 44 weeks: n = 5; vertical bars represented means ± SEM, fold-change cutoff = 2).
Figure 3.Effects of different crystallins on RGC survival under 60 mm Hg hydrostatic pressure in retina explants in vitro. (A–C) Representative fluorescence microscopy of Brn3a staining after 48 hours of cultivation with (B) or without (A) elevated hydrostatic pressure conditions (60 mm Hg), and with additional CRYAB (C). (D) After 48 hours of cultivation without pressure, it significantly reduced the number of the Brn3a positive RGCs to 918 ± 39.5/mm² (****P < 0.0001) and an additional 60 mm Hg of hydrostatic pressure further reduced the number of RGC to 678 ± 61.4/mm² (***P < 0.0005). All three crystallins significantly improved the RGC survival against elevated pressure, whereas CRYGB showed the most significant protective effect in vitro.
Figure 4.Immunodetection of α-crystallin B ( The left panel shows expression profile of the crystallins in the human retina. The middle and right panels represent expression profile of the crystallins in the rat retina. Corresponding expression profile of the crystallins can be seen in both human and rat retina. CRYAB, CRYBB2, and CRYGB are expressed in both human and rat retina and is predominantly detected in the ganglion cell layer (GCL) and weakly noted inner nuclear layer (INL) and outer nuclear layer (ONL). In both human and rat retina, immunoreactivity for CRYGB is weaker compared to CRYAB and CRYBB2 (scale bars = 20 µm).
Figure 5.Detection of endogenous crystallin in primary Müller cells. Primary Müller cells were fixed and then stained immunohistochemically against CRYAB, CRYBB2, and CRYGB. Cell nuclei are marked by DAPI (blue) and endogenous crystallins are shown in TRITC channel (red). All three crystallins can be detected in Müller cells. CRYAB showed the strongest fluorescent among all and a distinguishable diffuse distribution pattern throughout the Müller cells. The endogenous CRYBB2 and CRYGB showed weaker fluorescent and are distributed in the cytoplasm.
Figure 6.Intracellular uptake of crystallins in primarily isolated Müller cells from pig eyes. (A, B) Representative microscopy images of Müller cells incubated with labeled CRYAB. (A) Müller cells under light microscope, CRYAB in the TRITC channel, and cell nuclei in the DAPI channel. (B) Merged TRITC and DAPI channels, CRYAB can be seen accumulated in cytoplasm around nuclei. (D, E) Representative microscopy images of Müller cells incubated with labelled CRYBB2. (A) Müller cells under light microscope, CRYBB2 in the TRITC channel, and cell nuclei in the DAPI channel. (B) Merged TRITC and DAPI channels, CRYBB2 can be seen accumulated in cytoplasm around nuclei. (C, F, G) The signal intensity of all crystallins are increased in the Müller cells incubated with the respective crystallin. The intracellular abundance of CRYAB and CRYGB in the Müller cells are both significantly increased compared to the control, whereas the abundance of CRYBB2 in the Müller cells was not significantly changed (**P <0.01, n = 3; vertical bars represent means ± SD; scale bar = 50 µm).
Figure 7.The effect of α-crystallin B (CRYAB), β-crystallin B2 (CRYBB2), and γ-crystallin B (CRYGB) on the secretion of growth factors by primary Müller cells (A–I). The charts represent the median signal corresponding to the proteins bound with the dye Cy5. The growth factors CLU, VEGFA, MMP9, CRYAB, IL-6, CNTF, NGF, and TGFb2 are significantly upregulated (fold-change cutoff = 1.5; n = 5). (J) Protein-protein interaction network (from string-db.org) of the nine genes which are related to the uptake of the crystallins (medium confidence = 0.400).
Functional Enrichments in Network of Cytokines Upregulated in All Crystallin Groups
| GO -Term | Description | Strength | False Discovery Rate | Genes |
|---|---|---|---|---|
| Biological Process (Gene Ontology) | ||||
| GO: 0001974 | Blood vessel remodeling | 2.56 | 0.0064 |
|
| GO: 0061383 | Trabecula morphogenesis | 2.54 | 0.0064 |
|
| GO: 0003151 | Outflow tract morphogenesis | 2.35 | 0.0072 |
|
| GO: 0048771 | Tissue remodeling | 2.18 | 0.0038 |
|
| GO: 2001234 | Negative regulation of apoptotic signaling pathway | 1.93 | 0.0064 |
|
Enrichment Analysis by Biological Process of CRYAB-Regulated Proteins
| GO Term | Description | Strength | False Discovery Rate | Genes |
|---|---|---|---|---|
| Biological Process (Gene Ontology) | ||||
| GO: 1905907 | Negative regulation of amyloid fibril formation | 3.21 | 0.00071 |
|
| GO: 0061900 | Glial cell activation | 2.35 | 0.0050 |
|
| GO: 0045773 | Positive regulation of axon extension | 2.18 | 0.0086 |
|
Enrichment Analysis by Biological Process of CRYGB-Regulated Proteins
| GO Term | Description | Strength | False Discovery Rate | Genes |
|---|---|---|---|---|
| Biological Process (Gene Ontology) | ||||
| GO: 1905907 | Negative regulation of amyloid fibril formation | 3.1 | 0.00032 |
|
| GO: 0045429 | Positive regulation of nitric oxide biosynthetic process | 2.15 | 0.0060 |
|
| GO: 2001243 | Negative regulation of intrinsic apoptotic signaling pathway | 2.08 | 0.0003 |
|
| GO: 0048771 | Tissue remodeling | 2.05 | 2.42e-0.5 |
|